ArticleInternational journal of cancer2014
Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy.
Article in International journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.Cancer science · 2017Trial
- Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer.Immuno-oncology technology · 2026Review
- Review
- Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy.Materials today. Bio · 2022Review
- Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling.Oncoimmunology · 2022Article
- De-risking clinical trial failure through mechanistic simulation.Immunotherapy advances · 2022Article
- Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.Nature reviews. Clinical oncology · 2021Review
- Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities.Vaccines · 2021Review
- Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2International journal of breast cancer · 2021Article
- [Individualized immunotherapy for malignant tumors using peptide vaccines-maybe it does work after all?]Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020Review
- Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire.Nature reviews. Clinical oncology · 2020Review
- Review
- Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cellsOncotarget · 2020Article
- [Tumor vaccines-therapeutic vaccination against cancer].Der Internist · 2020Review
- Photochemically-Induced Release of Lysosomal Sequestered Sunitinib: Obstacles for Therapeutic Efficacy.Cancers · 2020Article
- Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.Frontiers in immunology · 2019Review
- Mechanisms of immune evasion in breast cancer.BMC cancer · 2018Review
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.Nature reviews. Clinical oncology · 2018Review
- Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.Therapeutic advances in urology · 2017Review
- Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Sunitinib, a protein tyrosine kinase inhibitor is the frontline therapy for renal and gastrointestinal cancers. We hypothesized that by virtue of its well documented tumor apoptosis and immune adjuvant properties, combination of Sunitinib with anti-tumor immunotherapeutics will provide synergistic inhibition of tumor growth. Our study was designed to evaluate the impact of Sunitinib on immunotherapy mediated anti-tumor immune responses and evaluate its efficacy as a combinatorial therapy with tumor targeted immunotherapeutic vaccination. Mice immunized with recombinant α-lactalbumin, a lactation protein expressed on majority of breast tumors were treated with 1 mg of Sunitinib for seven consecutive days beginning (1) concurrently, on the day of α-lactalbumin immunization or (2) sequentially, on day 9 after immunization. Ten-day lymph nodes or 21 day spleens were tested by ELISPOT assays and flow cytometry to evaluate responsiveness to α-lactalbumin immunization in presence of Sunitinib and distribution of cells involved in T cell antigen priming and proliferation in different lymphoid compartments. In addition, therapeutic efficacy of the α-lactalbumin/ Sunitinib combination was evaluated by monitoring tumor growth in the 4T1 transplanted tumor model. Our studies reveal that concurrent administration of Sunitinib with active vaccination against a targeted tumor antigen inhibits priming to the immunogen due to a drastic decrease in CD11b+CD11c+ antigen presenting cells, leading to failure of vaccination. However, sequential delivery of Sunitinib timed to avoid the priming phase of vaccination results in the desired vaccination mediated boost in immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.